Cargando…
Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease
BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) and pediatric-onset multiple sclerosis (POMS) share clinical and magnetic resonance imaging (MRI) features but differ in prognosis and management. Early POMS diagnosis is essential to avoid disability accumulat...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687802/ https://www.ncbi.nlm.nih.gov/pubmed/37897254 http://dx.doi.org/10.1177/13524585231204414 |
_version_ | 1785152047356575744 |
---|---|
author | Sacco, Simone Virupakshaiah, Akash Papinutto, Nico Schoeps, Vinicius A Akula, Amit Zhao, Haojun Arona, Jennifer Stern, William A Chong, Janet Hart, Janace Zamvil, Scott S Sati, Pascal Henry, Roland G Waubant, Emmanuelle |
author_facet | Sacco, Simone Virupakshaiah, Akash Papinutto, Nico Schoeps, Vinicius A Akula, Amit Zhao, Haojun Arona, Jennifer Stern, William A Chong, Janet Hart, Janace Zamvil, Scott S Sati, Pascal Henry, Roland G Waubant, Emmanuelle |
author_sort | Sacco, Simone |
collection | PubMed |
description | BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) and pediatric-onset multiple sclerosis (POMS) share clinical and magnetic resonance imaging (MRI) features but differ in prognosis and management. Early POMS diagnosis is essential to avoid disability accumulation. Central vein sign (CVS), paramagnetic rim lesions (PRLs), and central core lesions (CCLs) are susceptibility-based imaging (SbI)-related signs understudied in pediatric populations that may help discerning POMS from MOGAD. METHODS: T2-FLAIR and SbI (three-dimensional echoplanar imaging (3D-EPI)/susceptibility-weighted imaging (SWI) or similar) were acquired on 1.5T/3T scanners. Two readers assessed CVS-positive rate (%CVS+), and their average score was used to build a receiver operator curve (ROC) assessing the ability to discriminate disease type. PRLs and CCLs were identified using a consensual approach. RESULTS: The %CVS+ distinguished 26 POMS cases (mean age 13.7 years, 63% females, median EDSS 1.5) from 14 MOGAD cases (10.8 years, 35% females, EDSS 1.0) with ROC = 1, p < 0.0001, (cutoff 41%). PRLs were only detectable in POMS participants (mean 2.1±2.3, range 1–10), discriminating the two conditions with a sensitivity of 69% and a specificity of 100%. CCLs were more sensitive (81%) but less specific (71.43%). CONCLUSION: The %CVS+ and PRLs are highly specific markers of POMS. After proper validation on larger multicenter cohorts, consideration should be given to including such imaging markers for diagnosing POMS at disease onset. |
format | Online Article Text |
id | pubmed-10687802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-106878022023-12-01 Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease Sacco, Simone Virupakshaiah, Akash Papinutto, Nico Schoeps, Vinicius A Akula, Amit Zhao, Haojun Arona, Jennifer Stern, William A Chong, Janet Hart, Janace Zamvil, Scott S Sati, Pascal Henry, Roland G Waubant, Emmanuelle Mult Scler Original Research Papers BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) and pediatric-onset multiple sclerosis (POMS) share clinical and magnetic resonance imaging (MRI) features but differ in prognosis and management. Early POMS diagnosis is essential to avoid disability accumulation. Central vein sign (CVS), paramagnetic rim lesions (PRLs), and central core lesions (CCLs) are susceptibility-based imaging (SbI)-related signs understudied in pediatric populations that may help discerning POMS from MOGAD. METHODS: T2-FLAIR and SbI (three-dimensional echoplanar imaging (3D-EPI)/susceptibility-weighted imaging (SWI) or similar) were acquired on 1.5T/3T scanners. Two readers assessed CVS-positive rate (%CVS+), and their average score was used to build a receiver operator curve (ROC) assessing the ability to discriminate disease type. PRLs and CCLs were identified using a consensual approach. RESULTS: The %CVS+ distinguished 26 POMS cases (mean age 13.7 years, 63% females, median EDSS 1.5) from 14 MOGAD cases (10.8 years, 35% females, EDSS 1.0) with ROC = 1, p < 0.0001, (cutoff 41%). PRLs were only detectable in POMS participants (mean 2.1±2.3, range 1–10), discriminating the two conditions with a sensitivity of 69% and a specificity of 100%. CCLs were more sensitive (81%) but less specific (71.43%). CONCLUSION: The %CVS+ and PRLs are highly specific markers of POMS. After proper validation on larger multicenter cohorts, consideration should be given to including such imaging markers for diagnosing POMS at disease onset. SAGE Publications 2023-10-28 2023-12 /pmc/articles/PMC10687802/ /pubmed/37897254 http://dx.doi.org/10.1177/13524585231204414 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Papers Sacco, Simone Virupakshaiah, Akash Papinutto, Nico Schoeps, Vinicius A Akula, Amit Zhao, Haojun Arona, Jennifer Stern, William A Chong, Janet Hart, Janace Zamvil, Scott S Sati, Pascal Henry, Roland G Waubant, Emmanuelle Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease |
title | Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease |
title_full | Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease |
title_fullStr | Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease |
title_full_unstemmed | Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease |
title_short | Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease |
title_sort | susceptibility-based imaging aids accurate distinction of pediatric-onset ms from myelin oligodendrocyte glycoprotein antibody-associated disease |
topic | Original Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687802/ https://www.ncbi.nlm.nih.gov/pubmed/37897254 http://dx.doi.org/10.1177/13524585231204414 |
work_keys_str_mv | AT saccosimone susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT virupakshaiahakash susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT papinuttonico susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT schoepsviniciusa susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT akulaamit susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT zhaohaojun susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT aronajennifer susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT sternwilliama susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT chongjanet susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT hartjanace susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT zamvilscotts susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT satipascal susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT henryrolandg susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease AT waubantemmanuelle susceptibilitybasedimagingaidsaccuratedistinctionofpediatriconsetmsfrommyelinoligodendrocyteglycoproteinantibodyassociateddisease |